Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.
Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will participate in a Fireside Chat at 1:40 p.m. Eastern Time.
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors.
Markets are under some duress, but the action should not cause you to change your thesis. While markets are facing headwinds, it’s important to realize that stocks are under duress in what feels like a “shoot first, ask questions later” reaction.
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.
